Physician profile
Jin U O
NPI 1578746095
$3,792.97
in general payments reported to CMS, 2019-2025
25 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $169 · 2023: $967 · 2024: $1,594 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.73 | 2022-2025 | |
| Novo Nordisk INC | $691.23 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $586.94 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $333.58 | 2024-2025 | |
| Lilly USA, LLC | $240.19 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $167.28 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.67 | 2023-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $129.74 | 2022-2025 | |
| Corcept Therapeutics | $127.79 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $59.27 | 2024 | Veozah |
| Dexcom, INC. | $58.77 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $57.63 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.55 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $49.19 | 2024-2025 | Trelegy Ellipta |
| Amgen INC. | $47.30 | 2024-2025 | Repatha, Otezla, Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $38.29 | 2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $33.42 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $22.64 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.69 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.33 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $21.15 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $20.32 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $19.08 | 2022 | |
| Axsome Therapeutics, INC. | $17.31 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $14.88 | 2023 | Verquvo, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin O listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.